Lecanemab in Practice: Real‐World Data from a 6‐Month Follow‐Up in Early Alzheimer’s Disease
This 6-month follow-up highlights Lecanemab's potential to preserve cognitive function in early-stage AD, with a lower incidence of ARIA than reported in trials. These findings emphasize the importance of real-world evidence in shaping clinical practice for disease-modifying therapies.
Authors
- Dror Shir (ORCID: https://orcid.org/0000-0003-2811-3421)
- Tamara Shiner (ORCID: https://orcid.org/0000-0002-6368-9656)
- Aya Bar‐David
- Noa Trabulus
- Yifat Alcalay
- Noa Bregman (ORCID: https://orcid.org/0000-0003-4856-086X)
- Elissa L. Ash
- Talya Nathan
- Galia Wolpe
- Anan Abu‐Awad
- Mori Hay‐Levy
Institutions
- Tel Aviv University (IL)
- Tel Aviv Sourasky Medical Center (IL)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_102792
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00